Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT).Substance abuse treatment, prevention, and policy · 2024
   Article
2. The authors respond to "Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations".CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019
   Article

Corrections and comments

• Commented on by
  The authors respond to "Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations".2019
• Comment on
  Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.2019

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as